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OpProton pump inhibitor use and spontaneous bacterial peritonitis
in cirrhosis: An undesirable association?To the Editor:
It is well known that bacterial infections in cirrhotic patients are
associated with signiﬁcant morbidity and mortality, determining
a poor short- and long-term prognosis and a low survival rate [1].
In a recent issue, Terg et al. [2] published their experience on the
association between proton pump inhibitor (PPI) use and sponta-
neous bacterial peritonitis (SBP) in cirrhotic patients with ascites.
They found that, among 770 hospitalized cirrhotic patients, SBP
was diagnosed in 95 (24.7%) out of 394 patients with ascites
and that there was no signiﬁcant difference in the rate of PPI con-
sumption between patients with SBP and those with ascites, but
not with SBP (46% vs. 42%, p >0.05). Moreover, a high percentage
of cirrhotic patients were taking a PPI without any documented
indication (42%).
When we evaluated the incidence of SBP in 1030 cirrhotic
patients and its effect on survival [3], it was evident that SBP
was a common complication in patients with cirrhosis and ascites
(11.1%) and that it determined a poor prognosis (21.9% mortality
rate). We are currently performing a prospective study assessing
the incidence of SBP among cirrhotic outpatients using PPIs.
Among 582 cirrhotic patients followed-up for a median time of
5 years, 258 patients developed ascites and were evaluated
(Table 1). Among these, 151 were using PPIs (58.5%). SBP devel-
oped in 34 of the 151 patients who were using PPIs (22.5%) and
in 23 of the 107 patients who were not using PPIs (21.5%,
p = 0.176). In order to evaluate risk factors for the development
of SBP, a multivariate analysis was performed and showed that
only the Child-Turcotte-Pugh score was independently associated
with the incidence of SBP in cirrhotic outpatients [odds ratio of
2.09, 95% conﬁdence interval of 1.07–4.07; p = 0.029]. To the best
of our knowledge, there is only one study that evaluated the inci-
dence of SBP in a prospective cohort of cirrhotic outpatients using
PPIs and did not ﬁnd a difference between patients who used PPIs
and those who did not [4]. Nevertheless, in that study, the inci-
dence of SBP was evaluated in a small group with only 84 cir-
rhotic patients, of which 29 had ascites, and SBP was diagnosed
in nine patients.
Even though most studies describe an association between
the development of SBP and the use of PPIs, their results seem
to be limited by their retrospective character. We share the
understanding of Terg et al. [2], since, despite the indiscriminate
use of PPIs in cirrhotic patients, our experience, prospectively
evaluating cirrhotic outpatients, showed no signiﬁcant difference
in the incidence of SBP between the group of cirrhotics with
ascites who used PPIs and the group who did not.
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script and approved its ﬁnal version for publication.ble 1. Characteristics of the 258 patients with cirrhosis and ascites.
Using PPI
(n = 151)
Not using PPI
(n = 107)
p value
Age; years (mean ± SD) 54.7 ± 11.2 53.1 ± 11.3 0.26ª
Male gender; n (%) 95 (63.3) 67 (62.6) >0.99b
HCV-related etiology; n (%) 51 (34.5) 36 (34) 0.53b
CTP; n (%) 0.37b
A 64 (42.4) 39 (36.4)
B 64 (42.2) 55 (51.4)
C 23 (15.2) 13 (12.1)
MELD (mean ± SD) 12.5 ± 3.9 12.7 ± 3.8 0.71ª
SBP; n (%) 34 (22.5) 23 (21.5) 0.176
, standard deviation; n, number of patients; HCV, hepatitis C virus; CTP, Child-Turcotte-Pugh score; MELD, model for end stage liver disease.
tudent’s t test, bFisher’s exact test.
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Evidence supporting a beneﬁcial role of vitamin D in chronic
hepatitis C
To the Editor:
We read with interest the recent meta-analysis by Kitson et al.
[1]. The authors show that baseline vitamin D level is not associ-
ated with sustained virologic response (SVR) to pegylated inter-
feron (PegIFN) plus ribavirin therapy in patients with chronic
hepatitis C (CHC). Based on this ﬁnding, they question [1] the
non-skeletal beneﬁts of vitamin D supplements, an essential
determinant in regulating bone metabolism in chronic liver
disease [2], on CHC. However, as vitamin D deﬁciency has been
identiﬁed as a main risk factor for CHC development, we believe
that the non-skeletal beneﬁts of this kind of vitamin on patients
with CHC cannot be negligible and the conclusions of this meta-
analysis [1] needs to be further discussed and researched.
First, the studies included in the meta-analysis by Kitson et al.
[1] were performed in patients from America, Europe, Australia,
or Israel, all of whom were predominantly white in skin color.
Interestingly, a community-based cross-sectional study showed
that, compared with white people, blacks had lower levels of
vitamin D and vitamin D-binding protein [3]. In addition, poten-
tial differences were also observed between whites and blacks in
relation to the inﬂuence of vitamin D status in the degree of
hepatic ﬁbrosis in CHC patients [4]. As a consequence, levels of
vitamin D and its beneﬁts may vary in individuals with different
ethnicity, therefore the irrelevance between vitamin D and SVR,
and the ineffectiveness of vitamin D in CHC shown in this study,
needs to be also conﬁrmed in other races.
Second, this meta-analysis only summarized eleven studies,
seven of which, with 1951 patients, were published articles and
the other four were conference abstracts with less convincing
evidence. Among the eleven studies, the sole outlier, identiﬁed
by funnel and forest plots, belonged to a conference abstract.
Another coexisting meta-analysis with eleven full-text studies
demonstrated that a lower level of vitamin D was signiﬁcantly
associated with a lower probability of SVR in CHC patients receiv-
ing Peg-IFNa/ribavirin therapy, especially when a cut-off value of
20 ng/ml for vitamin D deﬁciency was adopted [5]. Furthermore,
a low vitamin D status was also found to be associated with a
higher risk of advanced liver ﬁbrosis in these patients [5].
Numerous clinical evidence also suggested that vitamin D sup-
plementation might protect against disease progression and ele-
vate the SVR rate following treatment for CHC [6,7]. Recurrence
of hepatitis C after liver transplantation is universal worldwide
[8]. In addition to its association with primary CHC, vitamin D
insufﬁciency could also result in a low SVR in patients with recur-
rent hepatitis C following antiviral therapy while vitamin D sup-
plementation signiﬁcantly improves the probability of achieving
a SVR [8].
Potential mechanisms that link vitamin D and CHC are
complex and varied. Treatment with vitamin D reduces the extra-
and intracellular levels of hepatitis C virus (HCV) core antigen in a
dose-dependent manner [9] and produces calcitriol which could
markably inhibit HCV productions [10], suggesting that vitamin
D plays a natural antiviral role. In addition, the anti-
inﬂammatory effects by reducing several pro-inﬂammatory
factors like TNF-a, IFN-c, and IL-17, as well as the anti-ﬁbrotic
role of vitamin D [7], might also partly explain the beneﬁts of this
vitamin supplementation in CHC.
As there is a global high prevalence of hypovitaminosis D
among CHC patients, it is crucial to determine the association
between vitamin D status/vitamin D supplementation and
outcomes of CHC. Larger, random clinical trials are still required
to conﬁrm the important non-skeletal effects of vitamin D in
patients with CHC.
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